Maze Therapeutics CSBO Dandekar divests $206,823 of common stock

Maze Therapeutics' Chief Strategy and Business Officer, Atul Dandekar, sold 7,500 shares of the company's common stock on August 28, 2026, for a total of $206,823. The sale was made under a pre-arranged Rule 10b5-1 trading plan, with shares traded at a weighted average price of $27.5765, varying between $27.31 and $28.01 per share.

The sale follows a year-long performance where the stock offered an 83% return, despite dropping 36% year-to-date from a 52-week high of $53.65. InvestingPro suggests the stock is overvalued at present levels. Prior to the sale, Dandekar bought the same number of shares by exercising stock options priced at $10.42 each, amounting to $78,150, which were fully vested as of March 17, 2025.

This purchase was also under the Rule 10b5-1 trading plan, initiated on September 29, 2025. Post these transactions, Dandekar owns 26,250 shares of Maze Therapeutics and additionally holds 14,143 derivative securities, specifically stock options.